Hardin Capital Partners LLC Acquires 823 Shares of Pfizer Inc. (NYSE:PFE)

Hardin Capital Partners LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 9,923 shares of the biopharmaceutical company’s stock after purchasing an additional 823 shares during the period. Hardin Capital Partners LLC’s holdings in Pfizer were worth $290,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Olistico Wealth LLC bought a new stake in shares of Pfizer during the second quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the second quarter worth approximately $29,000. Quarry LP bought a new stake in shares of Pfizer during the second quarter worth approximately $31,000. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. bought a new stake in shares of Pfizer during the second quarter worth approximately $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.2 %

Shares of NYSE:PFE opened at $29.22 on Friday. The company has a fifty day moving average of $29.07 and a 200-day moving average of $28.44. The company has a market capitalization of $165.58 billion, a PE ratio of -487.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the business earned $0.67 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.75%. Pfizer’s dividend payout ratio is -2,800.00%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday. They set a “market perform” rating and a $32.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Thursday, October 3rd. Wells Fargo & Company lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.